OR WAIT null SECS
Companies aim to simplify access to informative patient care data.
Guardant Health, a precision oncology company, and Flatiron Health, a health tech company, announced an initiative to integrate Guardant’s genomic profiling tests within Flatiron’s OncoEMR, a cloud-based electronic medical record (EMR) tool. Reportedly, the integration simplifies access to critical data that informs patient care decisions for over 2,000 clinicians within the Flatiron network, which includes more than 800 community-based cancer care locations across the US.
“Genomic profiling provides critical data that helps oncologists make timely and informed decisions about personalized treatment plans for their patients,” said Chris Freeman, chief commercial officer, Guardant Health. “This integration with the OncoEMR platform, which reaches almost 40 percent of U.S. community oncologists, will simplify access to our tests and enable a significant step forward in our mission to conquer cancer with data.”
Reference: Guardant Health, Flatiron Health Announce Integration of Guardant Genomic Profiling Tests Into OncoEMR® Platform. BusinessWire. October 31, 2023. Accessed October 31, 2023. https://www.businesswire.com/news/home/20231031158337/en/Guardant-Health-Flatiron-Health-Announce-Integration-of-Guardant-Genomic-Profiling-Tests-Into-OncoEMR%C2%AE-Platform